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The aimof this study is to quantify globalDNAmethylation and investigate the relationshipwith diabetes status and polymorphisms
inMTHFR C677T and NOS3 G894T genes in mixed ancestry subjects from South Africa. Global DNAmethylation was measured,
and MTHFR rs1801133 and NOS3 rs1799983 polymorphisms were genotyped using high throughput real-time polymerase chain
reaction and direct DNA sequencing. Of the 564 participants, 158 (28%) individuals had T2DM of which 97 (17.2%) were screen-
detected cases. Another 119 (21.1%) had prediabetes, that is, impaired fasting glucose, impaired glucose tolerance, or the combination
of both, and the remainder 287 (50.9%) had normal glucose tolerance. Global DNA methylation was significantly higher in
prediabetes and screen-detected diabetes than in normal glucose tolerance (both 𝑝 ≤ 0.033) and in screen-detected diabetes
compared to knowndiabetes on treatment (𝑝 = 0.019).Therewas no difference in globalDNAmethylation between knowndiabetes
on treatment and normal glucose tolerance (𝑝 > 0.999). In multivariable linear regression analysis, only NOS3 was associated with
increasing global DNA methylation (𝛽 = 0.943; 95% CI: 0.286 to 1.560). The association of global DNA methylation with screen-
detected diabetes but not treated diabetes suggests that glucose control agents to some extent may be reversing DNA methylation.
The association between NOS3 rs1799983 polymorphisms and DNA methylation suggests gene-epigenetic mechanisms through
which vascular diabetes complications develop despite adequate metabolic control.
1. Introduction
Type 2 diabetes mellitus (T2DM) results from an interaction
of environmental and genetic factors. Despite the initial
enthusiasm from the identification of risk loci for T2DM [1,
2], the clinical utility of these genetic markers for T2DM risk
prediction and reduction has remained limited. It is becom-
ing increasingly evident that the gene-environment interac-
tion in T2DM and other diseases can be explained in part by
epigenetics. Indeed, a number of recent studies using different
types of biological tissues from pancreas to peripheral blood
mononuclear cells (PBMCs) are showing that DNA methy-
lation patterns are altered in subjects with diabetes [3–6].
T2DM rates are increasing rapidly in African populations,
with traditional diabetes risk factors failing to explain a
great deal of these increases. Emerging alternate pathways
involve the interplay between epigenetics, microbiome, and
the immune system. Epigenetic mechanisms include DNA
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methylation, lysinemethylation, histonemethylation, histone
phosphorylation, RNA interference (RNAi), and genomic
imprinting [7]. DNA methylation is the most extensively
investigated epigenetic mechanism; however, DNA methy-
lation profiling of populations from Africa remains to be
investigated.
DNA methylation is an epigenetic process characterized
by a covalent modification with the addition of a methyl
group to the carbon at position 5 of cytosine nucleotides (H5),
process catalyzed DNA methyltransferases (DNMTs) [8]. S-
Adenosyl-methionine (SAM-CH3) donates themethyl group
in a process catalyzed by methylenetetrahydrofolate reduc-
tase (MTHFR), an important enzyme in the folate metabolic
pathway. Collectively, this folate and methionine cycles form
the transmethylation pathway, which is modulated by a num-
ber of genetic and environmental factors that in turn affect
DNA methylation [9]. In this regard, DNA hypomethylation
has been reported in liver biopsies of subjects with type 2
diabetes (T2DM) with low folate levels [10], while MTHFR
polymorphisms have been associated with decreased enzyme
activity. Two MTHFR polymorphisms, +677C/T (rs1801133)
and +1298A/C (rs1801131), have been widely studied and in
vitro studies have shown these polymorphisms to decrease
the enzyme activity by 35% and 60%, respectively [11, 12],
consequently causing DNA hypomethylation. Another gene
that has been shown to be affected by folate supplementation
is nitric oxide synthase (NOS) [13, 14]. Nitric oxide synthase
(eNOS, also referred to as NOS3) is an endothelial enzyme
whose function is to synthesize nitric oxide (NO) from L-
arginine [15, 16]. Nitric oxide is a unique molecule with
diverse physiologic regulatory functions such as smooth
muscle relaxation, inhibition of platelet aggregation, immune
regulation, neurotransmission, and blood pressure regulation
[17–19].
Therefore, this study was designed to examine global
DNA methylation in individuals with and without diabetes
and to evaluate whether polymorphisms in genes involved
in DNA methylation and/or folate metabolism, namely,
MTHFR and NOS3, have an effect on global DNA methyla-
tion in mixed ancestry subjects from South Africa.
2. Materials and Methods
2.1. Ethical Approval of the Study. The study was approved by
the Faculty of Health and Wellness Sciences Ethics Commit-
tee of the Cape Peninsula University of Technology (CPUT)
(NHREC: REC-230408-014) andwas conducted according to
the code of ethics of the World Medical Association (Decla-
ration of Helsinki, 1975). All participants who were recruited
for the study voluntarily signed written consent after the
procedures had been fully explained in the language of their
choice. Permission to conduct the study was granted by
relevant authorities such as city and community authorities
as previously described [20].
2.2. Study Design and Population. The present study was
cross-sectional by design, involving participants from a
mixed ancestry ethnic population group residing in Bellville
South Township in Cape Town, South Africa. A detailed
description of the survey and procedures conducted in the
study are available elsewhere [21, 22]. Eligible participants
were those who are older than 20 years, are residing in
Bellville South, are ofmixed ancestry origin, are not pregnant,
and are not acutely ill.
2.3. Clinical Data. Clinical data which has been previously
described [20] was collected in the form of a standardized
questionnaire. During this time physical examination was
conducted with data collection on blood pressure according
toWorldHealthOrganization (WHO) guidelines [23] using a
semiautomatic digital blood pressure monitor (Rossmax PA,
USA) on the right arm in sitting position and anthropometric
measurements. Body weight was measured to the nearest
0.1 kg with a Sunbeam EB710 digital bathroom scale, which
was calibrated and standardized using a weight of known
mass. Measurements were recorded with each subject wear-
ing light clothing, without shoes and socks. Waist circumfer-
ence was determined using a nonelastic tape at the level of the
narrowest part of the torso, as seen from the anterior view. All
anthropometric measurements were performed three times
and their average was used for analysis. Participants with no
history of doctor diagnosed diabetes mellitus underwent a
75 g oral glucose tolerance test (OGTT) as recommended by
WHO [24].
2.4. Biochemical Analysis. Blood samples were collected from
participants after overnight fast and processed as described
in [20]. Plasma glucose levels and glycated haemoglobin
(HbA1c) in whole blood collected in an EDTA tube were
measured, respectively, by enzymatic hexokinase method
and the turbidimetric inhibition immunoassay (Cobas 6000,
Roche Diagnostics, Germany). Serum insulin was deter-
mined by a microparticle enzyme immunoassay (AxSYM,
Abbott). High-density lipoprotein cholesterol (HDL-C) and
triglycerides (TG) were estimated by enzymatic colorimet-
ric methods in serum (Cobas 6000, Roche Diagnostics).
Low-density lipoprotein cholesterol (LDL-C) was calculated
using Friedwald’s formula [25]. Body mass index (BMI) was
calculated as weight/height ∗ height (kg/m2) and waist-
hip-ratio (WHR) as waist/hip circumference. Diabetes was
based on a history of doctor diagnosis, fasting blood glucose
concentration ≥ 7.0mmol/L (or 126mg/dL), and/or 2-hour
post-OGTT plasma glucose ≥ 11.1mmol/L (or 200mg/dL).
2.5. Genotyping and DNA Methylation. Genomic DNA was
extracted fromwhole blood samples collected in EDTA tubes
using the salt extraction method and quantified with the
NanoDrop ND-1000 instrument (Nanodrop Technologies,
Wilmington, USA). Global DNA methylation was measured
with the 5mC DNA ELISA kit according to the manu-
facturer’s instructions (Zymo Research Corp., Irvine, CA,
USA). Briefly, 100 ng of genomic DNA was allowed to bind
to the enzyme linked immunosorbent assay (ELISA) plate,
and the methylated fraction of DNA was detected using
a 5-methylcytosine monoclonal antibody and quantified by
an ELISA-like reaction and measuring the absorbance at
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450 nm. The MTHFR rs1801133 and NOS3 rs1799983 poly-
morphisms were genotyped using high throughput real-time
polymerase chain reaction (RT-PCR) on the BioRad Optica
(BioRad, USA) platform using Taqman genotyping assay
(Applied Biosystems, USA). Conventional polymerase chain
reaction followed by direct DNA sequencing was performed
for analytical validation of high throughput genotyping.
2.6. Statistical Analysis. General characteristics of the study
participants are summarized as count and percentage for
dichotomous traits andmedian and 25th–75th percentiles for
quantitative traits. Group comparisons used chi square and
Kruskal-Wallis tests. Monotonous trends in the distribution
of characteristics across quarters of global DNA methylation
were assessed using the Cochran-Armitage trend test for
proportions and Jonckheere-Terpstra trend test for medians.
Robust regressions were then used to assess the effect of var-
ious traits on global DNA methylation in models accounting
for age, gender, smoking, and glucose tolerance status. SNPs
were tested for departure from Hardy-Weinberg Equilibrium
(HWE) expectation via a chi square goodness of fit test, and
their effect on DNA methylation was investigated in linear
regressions models, while always assuming a log-additive
genetic model. Results corresponding to 𝑝 values below 5%
are described as significant. All analyses used the statistical
software R (version 3.2.2 (2015-08-14), R Foundation for
statistical computing, Vienna, Austria). SNPs analyses used
the packages “genetic” and “SNPassoc.”
3. Results
3.1. Global DNA Methylation and Cardiometabolic Profile.
The study cohort consisted of 564 participants, including 438
(78%) females.One hundred andfifty-eight (28%) individuals
had T2DM of which 97 (17.2%) were screen-detected cases.
Another one hundred and nineteen (21.1%) had prediabetes,
that is, impaired fasting glucose, impaired glucose tolerance,
or the combination of both, and the remainder 287 (50.9%)
had normal glucose tolerance. Global DNA methylation
(%) was significantly higher in subjects with prediabetes or
diabetes when compared to individuals with normoglycemia
(𝑝 < 0.05). However, no significant differences were observed
between subjects with prediabetes and diabetes. On further
analysis, higher global DNA methylation in diabetics was
driven by those with screen-detected diabetes. As shown in
Figure 1, global DNA methylation was significantly higher in
subjects with screen-detected diabetes than in thosewith nor-
moglycemia (𝑝 = 0.0003) and remained significantly higher
when compared to individuals with known diabetes (𝑝 =
0.019). However, there was no significant difference between
known diabetic and normoglycemia subjects (𝑝 > 0.999).
The characteristics of participants by glucose tolerance status
are summarized in Table 1, mostly showing the expected
differences.
The baseline characteristics of participants across quar-
ters of global DNA methylation are summarized in Table 2.
The proportion of participants with any diabetes increased
across increasing quarters of global DNA methylation
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Figure 1: Boxplot showing the distribution of global DNA methy-
lation across glucose tolerance status. Global DNAmethylation was
significantly higher in diabetic participants than in normotolerant
participants (𝑝 = 0.0003), significantly higher in screen-detected
diabetes than in known diabetes (𝑝 = 0.0188), and significantly
higher in prediabetes than in normal glucose tolerance (𝑝 =
0.0328). But there was no difference in global DNA methylation
between known diabetes and normal glucose tolerance (𝑝 > 0.999)
and between known diabetes and prediabetes (𝑝 = 0.408); all
𝑝 values are adjusted for multiple comparisons. Median global
DNA methylation (25th–75th percentiles): normal: 2.81 (0.68–4.62;
𝑁 = 284); prediabetes: 3.40 (1.53–5.45; 𝑁 = 120); screen-detected
diabetes: 4.62 (1.71–6.77;𝑁 = 97); known diabetes: 3.07 (0.80–4.45;
𝑁 = 61).
(𝑝 = 0.028) and in a linear fashion (𝑝 = 0.008 for linear
trend). Across quarters of global DNA methylation levels,
significant differences were also observed in the distribution
of fasting (𝑝 = 0.006) and 2-hour glucose levels (𝑝 = 0.002),
with increasing trends across quarters of global DNAmethy-
lation, always in linear fashions (both 𝑝 ≤ 0.003). Significant
correlations were also observed between global DNAmethy-
lation and diabetes (𝑟 = 0.101; 𝑝 = 0.016), body mass index
and waist circumference (both, 𝑟 = 0.09; 𝑝 = 0.033), fasting
blood glucose (𝑟 = 0.126; 𝑝 = 0.029), and after 2-hour blood
glucose (𝑟 = 0.167; 𝑝 = 0.0002). In robust linear regression
analysis adjusted for age, gender, status for hyperglycemia,
and smoking, any diabetes (𝛽 = 0.621; 𝑝 = 0.036) was asso-
ciated with global DNAmethylation.When participants with
diabetes were distinguished into those with screen-detected
diabetes or known diabetes, the association remained signifi-
cant only for screen-detected diabetes (𝛽 = 1.069; 𝑝 = 0.004)
but not for known diabetes. In similar regression analyses,
no other characteristics emerged as a significant predictor
of DNA methylation, although borderline associations were
observed with female gender, gamma-GT, and systolic blood
pressure (Table 2). The association of any diabetes with
DNA methylation also remained significant after expansion
of the basic models to include the following correlates of
diabetes status in the sample: BMI, waist circumference,
systolic blood pressure, drinking status, HDL-cholesterol,
total cholesterol, triglycerides, log-transformedCRP, and log-
transformed gamma-GT (𝛽 = 0.653; 𝑝 = 0.038).
3.2. Genetic Polymorphisms and DNA Methylation. Table 3
shows the genotype distribution of polymorphisms across
the quarters of global DNA methylation. None of the single
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Table 1: Characteristics according to glucose tolerance status.
Characteristic Normotolerant Prediabetes Screen-detected diabetes Known diabetes 𝑝 value
𝑛 (%) 283 (50.5) 119 (21.2) 97 (17.3) 61 (10.9)
Median actual% 5mc 2.83 (0.71–4.62) 3.41 (1.55–5.45) 4.62 (1.71–6.77) 3.07 (0.80–4.45) 0.0001
Women, 𝑛 (%) 215 (76.0) 98 (82.3) 81 (83.5) 40 (65.6) 0.030
Current smoking, 𝑛 (%) 121 (42.8) 44 (37.0) 35 (36.1) 20 (32.8) 0.363
Current drinking, 𝑛 (%) 80 (28.3) 33 (27.7) 25 (25.8) 12 (19.7) 0.573
Age (years) 49.7 (13.5) 54.0 (12.0) 58.0 (13.3) 58.3 (11.4) <0.0001
Body mass index (kg/m2) 28.7 (7.2) 31.2 (7.1) 32.5 (7.3) 30.5 (6.6) <0.0001
Waist circumference (cm) 93 (14) 99 (15) 102 (16) 101 (14) <0.0001
Hip circumference (cm) 108 (15) 112 (14) 114 (15) 109 (15) 0.007
Waist-to-hip ratio 0.86 (0.07) 0.89 (0.09) 0.89 (0.08) 0.92 (0.08) <0.0001
Systolic blood pressure (mmHg) 119 (18) 122 (15) 129 (21) 128 (18) <0.0001
Diastolic blood pressure (mmHg) 74 (11) 74 (10) 76 (12) 75 (12) 0.323
Fasting blood glucose (mmol/L) 5.0 (0.7) 5.7 (0.5) 8.5 (3.4) 11.1 (4.2) <0.0001
2-hour glucose (mmol/L) 5.9 (1.0) 8.6 (1.1) 13.9 (5.7) NA <0.0001
HbA1c (%) 5.7 (0.4) 5.8 (0.4) 7.1 (1.8) 8.3 (1.8) <0.0001
Fasting insulin (𝜇U/mL) 6.2 (3.0–10.6) 7.2 (1.9–12.7) 9.3 (3.7–16.1) 8.0 (2.8–12.8) 0.013
2-hour insulin (𝜇U/mL) 33.9 (17.1–54.4) 58.2 (26.1–97.9) 56.6 (21.2–108.6) NA <0.0001
C-reactive protein (mg/L) 2.8 (0.7–7.1) 6.6 (1.8–12.6) 6.4 (2.1–11.8) 4.0 (1.3–7.6) <0.0001
Cotinine (ng/mL) 10.0 (9.0–307.5) 10.0 (9.0–270.2) 10.0 (9.0–213.0) 10.0 (9.0–125.2) 0.514
Gamma-glutamyltransferase (IU/L) 25.0 (17.0–36.5) 29.0 (22.0–41.0) 33.0 (24.0–54.0) 29.5 (20.0–45.7) <0.0001
Triglycerides (mmol/L) 1.1 (0.8–1.4) 1.4 (1.1–1.8) 1.6 (1.2–2.1) 1.6 (1.2–2.2) <0.0001
HDL-cholesterol (mmol/L) 1.3 (0.3) 1.3 (0.3) 1.3 (0.3) 1.1 (0.3) 0.007
LDL-cholesterol (mmol/L) 3.6 (1.0) 3.6 (1.0) 4.0 (1.1) 3.3 (1.1) 0.0001
Total cholesterol (mmol/L) 5.5 (1.2) 5.6 (1.1) 6.1 (1.3) 5.3 (1.1) <0.0001
Values are count (percentages), mean (standard deviation), or median (25th–75th percentiles).
nucleotide polymorphisms (SNPs) deviated from Hardy-
Weinberg Equilibrium (HWE) (all 𝑝 ≥ 0.582), and their
distribution showed neither significant difference (all 𝑝 ≥
0.173) nor linear trends (all 𝑝 ≥ 0.205 for linear trend) across
the quarters of global DNA methylation. In linear regression
analysis adjusted for age, gender, status for hyperglycemia,
and smoking, only T allele of NOS3 was associated with
increasing global DNA methylation with a beta coefficient
of 0.943 (95% confidence interval: 0.286 to 1.560) assuming
a log-additive genetic model. This association remained sig-
nificant in sensitivity analysis after exclusion of participants
with known diabetes. In this subgroup, the beta coefficient
was 1.102 (95% CI: 0.401 to 1.802) for the effect of T allele of
NOS3 on global DNA methylation.
4. Discussion
In this study, we measured global DNA methylation in
PBMCs of mixed ancestry individuals with different levels of
glucose tolerance, in parallel with genetic screening of poly-
morphisms in theMTHFR andNOS3 genes. Our results show
that global DNAmethylation is increased in both prediabetic
and diabetic states, but this increase was more pronounced
in those with screen-detected diabetes, even after adjustment
for extraneous factors such as age, gender, smoking, and
glucose tolerance status. The distribution of the investigated
SNPs did not differ across quarters of DNA methylation,
but regression analysis under log-additive genetic model
assumption revealedNOS3 to be an independent determinant
of global DNA methylation.
The strengths of our study include a well-characterized
cohort and using the reference standard OGTT and a
detailed drug history to carefully assign individuals to glucose
tolerance status. Both T2DM and DNA methylation are
affected by age, obesity, and genetic factors. In this regard,
we also evaluated the effect of genes involved in DNA
methylation and/or folate metabolism. We quantified DNA
methylation across the whole genome using enzyme linked
immunosorbent assay (ELISA), which is cost-effective and
easy technique that is amenable for routine analysis in
developing countries. The use of robust analytic methods
also increases the reliability of our findings. For instance,
by implementing robust correlations to eliminate the effect
of outliers, we provide better estimates of the measures of
association without loss of power [26].
In this study, we show that DNA methylation is signif-
icantly increased in subjects with screen-detected diabetes
compared to those with diabetes and those on treatment. We
believe that the lack of association between known diabetes
and global DNA methylation in our sample is likely due to
the reversal of DNAmethylation changes by glucose controls
agents in these individuals. These findings are in contrast
with a study that quantified global DNA methylation by
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Table 3: Genotype distribution across the quarters of global DNA methylation.
Characteristic Global DNA methylation 𝑝 difference∗ 𝑝-trend 𝑝HWE 𝛽 (95% CI)∗∗∗
Q1 Q2 Q3 Q4
𝑛 111 110 112 111
Actual% 5mc
Median 0.11 2.12 3.94 7.24
MTHFR rs1801133 0.665 0.255 0.697 −0.387 (−1.054 to 0.281)
C/C 75 (68.8) 78 (71.6) 85 (76.6) 86 (77.5)
C/T 32 (29.4) 27 (24.8) 24 (21.6) 23 (20.7)
T/T 2 (1.8) 4 (3.7) 2 (1.8) 2 (1.8)
NOS3 rs1799983 0.173 0.205 0.582 0.943 (0.286 to 1.560)
G/G 82 (76.6) 73 (68.9) 81 (77.1) 65 (62.5)
G/T 23 (21.5) 28 (26.4) 22 (20.9) 36 (34.6)
T/T 2 (1.9) 5 (4.7) 2 (1.9) 3 (2.9)
∗𝑝 values from Kruskal-Wallis and chi square tests for the differences across quarters of global DNA methylation.
∗∗∗Beta coefficients and 95% confidence interval from age, gender, and status for hyperglycemia and smoking adjusted linear regressions for the prediction of
global DNA methylation by various SNPs assuming a log-additive genetic model.
HWE: Hardy-Weinberg equilibrium.
bisulfite pyrosequencing and showed a null effect of diabetes
medication on the association between DNA methylation
and insulin resistance [27]. The difference between Zhao
et al. [27] and our study may be attributed to the sample
size of these two studies. Their study analyzed global DNA
methylation of 17 diabetics on glucose control agents, whereas
61 diabetics on medication were included in our study.
Genetic polymorphisms have been shown to be responsible
for individual responses to many oral antidiabetic drugs
[28, 29], and these polymorphisms may also be subject to
epigenetic regulation. It is thought that antidiabetic drugs
could influence methylation trends through gene expression
mechanisms andmay represent a possible confounding factor
for the identification of T2DM related epigenetic profiles
[3]. Furthermore, our results are in contrast with those
reported in liver biopsies of subjects with T2DM where
genome-wide analysis of DNA methylation identified 94%
hypomethylatedCpG sites in these individuals [10]. Although
diabetic subjects in this study were similarly obese as in
Nilsson et al. [10], the differences in the cell types and liver
versus blood leucocytes as well as the different methods for
quantifying DNA methylation may explain differences in
DNA methylation.
Although global DNA methylation correlated positively
with adiposity indices, there was no correlation with age.
The lack of association between DNA methylation and age
is at variance with a number of studies that have repeatedly
shown decreasingDNAmethylation with increasing age [30–
32]. The narrow age range in our study has likely masked any
association between DNA methylation and age. We also did
not find an association between theMTHFRC677Tpolymor-
phism and global DNAmethylation, despite previous reports
that have shown an association between MTHFR C677T,
methyl group generation, and subsequent DNA methylation
[33, 34]. Contrary to our prior hypothesis that MTHFR
gene polymorphisms will affect global DNA methylation,
we observed that global DNA methylation was associated
with NOS3 G894T polymorphism. Reduced production of
NO is one of the most important contributors to endothelial
dysfunction, an initiator of vascular complications [15–19].
NOS3 is encoded by the NOS3 gene located on chromosome
7q35-36 and three polymorphisms (G894T, 4b/a, and T786C)
in the NOS3 gene are associated with diabetes and diabetes
related traits and reduced enzyme activity and consequently
bioavailability of NO and endothelial function [19, 35, 36]. It
is not clear how NOS3 may influence global DNA methy-
lation, but a study involving obese children and type 1 dia-
betes with NOS3 polymorphisms demonstrated an improved
endothelial function after supplementation with folate [37].
Similarly, the authors obtained differing results with respect
to MTHFR as no improvement in endothelial function was
evident in those with MTHFR polymorphisms suggesting
two independent mechanisms for vascular response to folate
for both NOS3 and MTHFR [37]. Folate plays an important
role in DNA methylation and several studies have shown
aberrant DNAmethylation profiles in relation to folate levels
[10, 38]. Individuals with T2DM are at an increased risk
of both micro- and macrovascular complications and it has
previously been shown that glycemic control is not adequate
to halt the progression of vascular complications [39–41].
Thus, the observed association between NOS3 G894T gene
polymorphisms and global DNA methylation suggests gene-
epigenetic mechanisms through which vascular complica-
tions develop despite adequate glycemic control in individ-
uals with T2DM.
The current study represents a significant contribution in
the African setting, where research about the contribution
of epigenetics to the growing burden of noncommunicable
disease in the region is lacking [42]. In summary, our
data indicates that global DNA methylation is significantly
associated with screen-detected diabetes compared to known
diabetes on treatment, leading us to speculate that glucose
control agents to some extent may be reversing DNAmethy-
lation. Furthermore, we showed that DNA methylation is
Journal of Diabetes Research 7
independent of MTHFR polymorphism but is influenced by
NOS3 gene polymorphismG894T. It is known that epigenetic
variations are regulated in a tissue-specific manner; however,
the use of peripheral blood to assess DNA methylation is
recommended for epidemiologic samples [43]. Furthermore,
DNA methylation in blood presents a feasible marker for
the diagnosis, prevention, and management of T2DM. To
fully elucidate the role of DNA methylation in this popula-
tion, future studies should explore gene-specific methylation
together with global DNA methylation analysis.
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